July 14 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS ENGAGES GLOBAL CRO TO CONDUCT LSALT PEPTIDE (METABLOK) PHASE II TRIAL FOR TREATMENT OF COMPLICATIONS IN COVID-19 PATIENTS IN THE U.S.
* ARCH BIOPARTNERS - PHASE 1 STUDY IN 52 HEALTHY MALE & FEMALE VOLUNTEERS IS COMPLETE WITH LSALT PEPTIDE MEETING PRIMARY ENDPOINT OF SAFETY, TOLERABILITY